argenx SE Investor Day Presentation Deck
Myositis: IgG-Mediated Biology
Neuromuscular Disease
Neuromuscular Disease
Neuromuscular Disease
argenx
Myasthenia Gravis
Chronic Inflammatory
Demyelinating
Polyneuropathy
Myositis
ACHR, MUSK, LRP4
autoantibodies comprise +
~90% of MG patients
40% anti-myelinated
peripheral nerve IgGs
+
Autoantibodies characterized
in 70% of patients across +
IMNM, ASYS and DM
IND filing by end of 2021 pending interactions with FDA
ADAPT Data
ADHERE
GO/NO-GO
Next
Opportunity
IMNM: Immune-Mediated Necrotizing Myopathy ASyS: Anti-Synthetase Syndrome DM: Dermatomyositis
Gilhus et al., Nature Rev/Disease Primers. 2019; Gilhus et al., NEJM, 2016; Querol et al., Nat Rev Neurol. 2017; Schmidt, Journal Neuromusc Diseases. 2018; Aquilar-Vazquez et al., Frontiers in Immunology. 2021; McHugh,
Managing Myositis. 2019
10View entire presentation